The Lyssavirus glycoprotein: A key to cross-immunity
Autor: | Sindisiwe G. Buthelezi, Lennart Martens, Tsepo L. Tsekoa, Rachel Chikwamba, Heini W. Dirr, Stoyan Stoychev, Ereck Chakauya, Elien Vandermarliere |
---|---|
Rok vydání: | 2016 |
Předmět: |
Models
Molecular 0301 basic medicine Protein Conformation Cross immunity Cross Reactions Antibodies Viral medicine.disease_cause Epitope Conserved sequence Viral Proteins 03 medical and health sciences Neutralization Tests Rhabdoviridae Infections Virology medicine Antigens Viral Lyssavirus Conserved Sequence Phylogeny Glycoproteins chemistry.chemical_classification biology Rabies virus biology.organism_classification medicine.disease Antibodies Neutralizing 030104 developmental biology chemistry biology.protein Epitopes B-Lymphocyte Rabies Antibody Glycoprotein |
Zdroj: | Virology. 498:250-256 |
ISSN: | 0042-6822 |
Popis: | Rabies is an acute viral encephalomyelitis in warm-blooded vertebrates, caused by viruses belonging to Rhabdovirus family and genus Lyssavirus. Although rabies is categorised as a neglected disease, the rabies virus (RABV) is the most studied amongst Lyssaviruses which show nearly identical infection patterns. In efforts to improving post-exposure prophylaxis, several anti-rabies monoclonal antibodies (mAbs) targeting the glycoprotein (G protein) sites I, II, III and G5 have been characterized. To explore cross-neutralization capacity of available mAbs and discover new possible B-cell epitopes, we have analyzed all available glycoprotein sequences from Lyssaviruses with a focus on sequence variation and conservation. This information was mapped on the structure of a representative G protein. We proposed several possible cross-neutralizing B-cell epitopes (GUVTTTF, WLRTV, REECLD and EHLVVEEL) in complement to the already well-characterized antigenic sites. The research could facilitate development of novel cross-reactive mAbs against RABV and even more broad, against possibly all Lyssavirus members. |
Databáze: | OpenAIRE |
Externí odkaz: |